{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:52:48Z","timestamp":1791975168064,"version":"4.4.0"},"reference-count":196,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T00:00:00Z","timestamp":1784419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02252-x","type":"journal-article","created":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T05:04:14Z","timestamp":1784437454000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ncRNA-driven regulation of PD-L1 in breast cancer: mechanisms of immune escape and therapeutic opportunities"],"prefix":"10.1007","volume":"26","author":[{"given":"Amirhossein","family":"Mardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajjad Rajabi","family":"Moghaddam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Roohi","family":"Motlagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirreza","family":"Mehmandar-Oskuie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,19]]},"reference":[{"issue":"6","key":"2252_CR1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3322\/caac.21863","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, et al. Breast cancer statistics 2024. Cancer J Clin. 2024;74(6):477\u201395.","journal-title":"Cancer J Clin"},{"issue":"02","key":"2252_CR2","first-page":"2022","volume":"9","author":"M Komuravelli","year":"2022","unstructured":"Komuravelli M, Gaddala A, Nama S, Matli P, Anchuri K. Awareness and Attitude Regarding the Risk Factors, and Self Examination for Breast Cancer in the Students of an Engineering College of South India. Eur J Mol Clin Med (EJMCM). 2022;9(02):2022.","journal-title":"Eur J Mol Clin Med (EJMCM)"},{"issue":"3","key":"2252_CR3","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"2252_CR4","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.7150\/ijbs.21635","volume":"13","author":"YS Sun","year":"2017","unstructured":"Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, et al. Risk Factors and Preventions of Breast Cancer. Int J Biol Sci. 2017;13(11):1387\u201397.","journal-title":"Int J Biol Sci"},{"issue":"5","key":"2252_CR5","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3892\/or_00000963","volume":"24","author":"MS Hassan","year":"2010","unstructured":"Hassan MS, Ansari J, Spooner D, Hussain SA. Chemotherapy for breast cancer (Review). Oncol Rep. 2010;24(5):1121\u201331.","journal-title":"Oncol Rep"},{"issue":"9503","key":"2252_CR6","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/S0140-6736(05)67887-7","volume":"366","author":"M Clarke","year":"2005","unstructured":"Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087\u2013106.","journal-title":"Lancet"},{"issue":"18","key":"2252_CR7","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1001\/jama.2009.1568","volume":"302","author":"R Gartner","year":"2009","unstructured":"Gartner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA. 2009;302(18):1985\u201392.","journal-title":"JAMA"},{"issue":"1","key":"2252_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10549-007-9523-x","volume":"107","author":"A Fournier","year":"2008","unstructured":"Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103\u201311.","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"2252_CR9","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1038\/bjc.1996.532","volume":"74","author":"DW Miles","year":"1996","unstructured":"Miles DW, Towlson KE, Graham R, Reddish M, Longenecker BM, Taylor-Papadimitriou J, et al. A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br J Cancer. 1996;74(8):1292\u20136.","journal-title":"Br J Cancer"},{"issue":"1","key":"2252_CR10","first-page":"72","volume":"19","author":"J Huszno","year":"2015","unstructured":"Huszno J, Budryk M, Kolosza Z, Nowara E. The risk factors of toxicity during chemotherapy and radiotherapy in breast cancer patients according to the presence of BRCA gene mutation. Contemp Oncol (Pozn). 2015;19(1):72\u20136.","journal-title":"Contemp Oncol (Pozn)"},{"issue":"2","key":"2252_CR11","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.canlet.2016.07.018","volume":"380","author":"A Pavlopoulou","year":"2016","unstructured":"Pavlopoulou A, Oktay Y, Vougas K, Louka M, Vorgias CE, Georgakilas AG. Determinants of resistance to chemotherapy and ionizing radiation in breast cancer stem cells. Cancer Lett. 2016;380(2):485\u201393.","journal-title":"Cancer Lett"},{"issue":"1","key":"2252_CR12","first-page":"62","volume":"1","author":"G Li","year":"2025","unstructured":"Li G, Wan Y, Jiao A, Jiang K, Cui G, Tang J, et al. Breaking boundaries: chronic diseases and the frontiers of immune microenvironments. Med Res. 2025;1(1):62\u2013102.","journal-title":"Med Res"},{"issue":"7414","key":"2252_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature11233","volume":"489","author":"S Djebali","year":"2012","unstructured":"Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, et al. Landscape of transcription in human cells. Nature. 2012;489(7414):101\u20138.","journal-title":"Nature"},{"issue":"1","key":"2252_CR14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.tibs.2013.10.002","volume":"39","author":"L Yang","year":"2014","unstructured":"Yang L, Froberg JE, Lee JT. Long noncoding RNAs: fresh perspectives into the RNA world. Trends Biochem Sci. 2014;39(1):35\u201343.","journal-title":"Trends Biochem Sci"},{"issue":"11","key":"2252_CR15","doi-asserted-by":"crossref","first-page":"582","DOI":"10.5732\/cjc.013.10170","volume":"32","author":"T Huang","year":"2013","unstructured":"Huang T, Alvarez A, Hu B, Cheng SY. Noncoding RNAs in cancer and cancer stem cells. Chin J Cancer. 2013;32(11):582\u201393.","journal-title":"Chin J Cancer"},{"issue":"9","key":"2252_CR16","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1631\/jzus.B1900709","volume":"21","author":"J Xu","year":"2020","unstructured":"Xu J, Wu KJ, Jia QJ, Ding XF. Roles of miRNA and lncRNA in triple-negative breast cancer. J Zhejiang Univ Sci B. 2020;21(9):673\u201389.","journal-title":"J Zhejiang Univ Sci B"},{"key":"2252_CR17","doi-asserted-by":"crossref","unstructured":"Le P, Romano G, Nana-Sinkam P, Acunzo M. Non-Coding RNAs in Cancer Diagnosis and Therapy: Focus on Lung Cancer. Cancers (Basel). 2021;13(6).","DOI":"10.3390\/cancers13061372"},{"key":"2252_CR18","first-page":"251513552311920","volume":"11","author":"AN Kamali","year":"2023","unstructured":"Kamali AN, Bautista JM, Eisenhut M, Hamedifar H. Immune checkpoints and cancer immunotherapies: insights into newly potential receptors and ligands. Ther Adv Vaccines Immunother. 2023;11:25151355231192043.","journal-title":"Ther Adv Vaccines Immunother"},{"issue":"2","key":"2252_CR19","doi-asserted-by":"crossref","first-page":"151875","DOI":"10.1016\/j.imbio.2019.11.010","volume":"225","author":"N Taefehshokr","year":"2020","unstructured":"Taefehshokr N, Baradaran B, Baghbanzadeh A, Taefehshokr S. Promising approaches in cancer immunotherapy. Immunobiology. 2020;225(2):151875.","journal-title":"Immunobiology"},{"issue":"12","key":"2252_CR20","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/70932","volume":"5","author":"H Dong","year":"1999","unstructured":"Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5(12):1365\u20139.","journal-title":"Nat Med"},{"issue":"3","key":"2252_CR21","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","volume":"48","author":"C Sun","year":"2018","unstructured":"Sun C, Mezzadra R, Schumacher TN. Regulation and Function of the PD-L1 Checkpoint. Immunity. 2018;48(3):434\u201352.","journal-title":"Immunity"},{"key":"2252_CR22","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704.","journal-title":"Annu Rev Immunol"},{"issue":"7","key":"2252_CR23","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027\u201334.","journal-title":"J Exp Med"},{"issue":"2","key":"2252_CR24","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.cell.2019.02.016","volume":"177","author":"M Poggio","year":"2019","unstructured":"Poggio M, Hu T, Pai CC, Chu B, Belair CD, Chang A, et al. Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory. Cell. 2019;177(2):414\u201327. e13.","journal-title":"Cell"},{"issue":"8","key":"2252_CR25","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793\u2013800.","journal-title":"Nat Med"},{"issue":"9","key":"2252_CR26","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563\u201380.","journal-title":"Nat Rev Clin Oncol"},{"key":"2252_CR27","doi-asserted-by":"crossref","first-page":"1167975","DOI":"10.3389\/fimmu.2023.1167975","volume":"14","author":"Q Yin","year":"2023","unstructured":"Yin Q, Wu L, Han L, Zheng X, Tong R, Li L, et al. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023;14:1167975.","journal-title":"Front Immunol"},{"key":"2252_CR28","doi-asserted-by":"crossref","unstructured":"Li Y, Al Hallak MN, Philip PA, Azmi AS, Mohammad RM. Non-Coding RNAs in Pancreatic Cancer Diagnostics and Therapy: Focus on lncRNAs, circRNAs, and piRNAs. Cancers (Basel). 2021;13(16).","DOI":"10.3390\/cancers13164161"},{"key":"2252_CR29","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.omto.2021.07.001","volume":"22","author":"CG Liu","year":"2021","unstructured":"Liu CG, Li J, Xu Y, Li W, Fang SX, Zhang Q, et al. Long non-coding RNAs and circular RNAs in tumor angiogenesis: From mechanisms to clinical significance. Mol Ther Oncolytics. 2021;22:336\u201354.","journal-title":"Mol Ther Oncolytics"},{"issue":"4","key":"2252_CR30","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cell.2009.02.006","volume":"136","author":"CP Ponting","year":"2009","unstructured":"Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136(4):629\u201341.","journal-title":"Cell"},{"issue":"3","key":"2252_CR31","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.molcel.2018.06.034","volume":"71","author":"X Li","year":"2018","unstructured":"Li X, Yang L, Chen LL. The Biogenesis, Functions, and Challenges of Circular RNAs. Mol Cell. 2018;71(3):428\u201342.","journal-title":"Mol Cell"},{"issue":"1","key":"2252_CR32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1476-4598-10-38","volume":"10","author":"EA Gibb","year":"2011","unstructured":"Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer. 2011;10(1):38.","journal-title":"Mol Cancer"},{"issue":"2","key":"2252_CR33","doi-asserted-by":"crossref","first-page":"241","DOI":"10.32604\/or.2023.046582","volume":"32","author":"X Huang","year":"2023","unstructured":"Huang X, Song C, Zhang J, Zhu L, Tang H. Circular RNAs in breast cancer diagnosis, treatment and prognosis. Oncol Res. 2023;32(2):241\u20139.","journal-title":"Oncol Res"},{"issue":"11","key":"2252_CR34","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41576-019-0158-7","volume":"20","author":"LS Kristensen","year":"2019","unstructured":"Kristensen LS, Andersen MS, Stagsted LVW, Ebbesen KK, Hansen TB, Kjems J. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20(11):675\u201391.","journal-title":"Nat Rev Genet"},{"key":"2252_CR35","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3389\/fendo.2018.00402","volume":"9","author":"J O\u2019Brien","year":"2018","unstructured":"O\u2019Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front Endocrinol (Lausanne). 2018;9:402.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10A","key":"2252_CR36","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1101\/gr.2722704","volume":"14","author":"A Rodriguez","year":"2004","unstructured":"Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identification of mammalian microRNA host genes and transcription units. Genome Res. 2004;14(10A):1902\u201310.","journal-title":"Genome Res"},{"issue":"7149","key":"2252_CR37","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nature05983","volume":"448","author":"JG Ruby","year":"2007","unstructured":"Ruby JG, Jan CH, Bartel DP. Intronic microRNA precursors that bypass Drosha processing. Nature. 2007;448(7149):83\u20136.","journal-title":"Nature"},{"issue":"2","key":"2252_CR38","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jmb.2004.03.065","volume":"339","author":"A Tanzer","year":"2004","unstructured":"Tanzer A, Stadler PF. Molecular evolution of a microRNA cluster. J Mol Biol. 2004;339(2):327\u201335.","journal-title":"J Mol Biol"},{"issue":"2","key":"2252_CR39","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","volume":"136","author":"DP Bartel","year":"2009","unstructured":"Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215\u201333.","journal-title":"Cell"},{"issue":"7027","key":"2252_CR40","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nature03315","volume":"433","author":"LP Lim","year":"2005","unstructured":"Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433(7027):769\u201373.","journal-title":"Nature"},{"issue":"5","key":"2252_CR41","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/ng1536","volume":"37","author":"A Krek","year":"2005","unstructured":"Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, et al. Combinatorial microRNA target predictions. Nat Genet. 2005;37(5):495\u2013500.","journal-title":"Nat Genet"},{"issue":"2","key":"2252_CR42","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.molcel.2016.09.004","volume":"64","author":"JP Broughton","year":"2016","unstructured":"Broughton JP, Lovci MT, Huang JL, Yeo GW, Pasquinelli AE. Pairing beyond the Seed Supports MicroRNA Targeting Specificity. Mol Cell. 2016;64(2):320\u201333.","journal-title":"Mol Cell"},{"issue":"1","key":"2252_CR43","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41580-018-0045-7","volume":"20","author":"LFR Gebert","year":"2019","unstructured":"Gebert LFR, MacRae IJ. Regulation of microRNA function in animals. Nat Rev Mol Cell Biol. 2019;20(1):21\u201337.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"9","key":"2252_CR44","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.tibs.2014.07.004","volume":"39","author":"D Schraivogel","year":"2014","unstructured":"Schraivogel D, Meister G. Import routes and nuclear functions of Argonaute and other small RNA-silencing proteins. Trends Biochem Sci. 2014;39(9):420\u201331.","journal-title":"Trends Biochem Sci"},{"key":"2252_CR45","doi-asserted-by":"crossref","first-page":"15004","DOI":"10.1038\/sigtrans.2015.4","volume":"1","author":"Y Peng","year":"2016","unstructured":"Peng Y, Croce CM. The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 2016;1:15004.","journal-title":"Signal Transduct Target Ther"},{"key":"2252_CR46","doi-asserted-by":"crossref","unstructured":"Mizielska A, Dziechciowska I, Szczepanski R, Cisek M, Dabrowska M, Slezak J et al. Doxorubicin and Cisplatin Modulate miR-21, miR-106, miR-126, miR-155 and miR-199 Levels in MCF7, MDA-MB-231 and SK-BR-3 Cells That Makes Them Potential Elements of the DNA-Damaging Drug Treatment Response Monitoring in Breast Cancer Cells-A Preliminary Study. Genes (Basel). 2023;14(3).","DOI":"10.3390\/genes14030702"},{"issue":"8","key":"2252_CR47","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/1061186X.2023.2240979","volume":"31","author":"SM Ahmadi","year":"2023","unstructured":"Ahmadi SM, Amirkhanloo S, Yazdian-Robati R, Ebrahimi H, Pirhayati FH, Almalki WH, et al. Recent advances in novel miRNA mediated approaches for targeting breast cancer. J Drug Target. 2023;31(8):777\u201393.","journal-title":"J Drug Target"},{"key":"2252_CR48","doi-asserted-by":"crossref","unstructured":"Lukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanislawek A. Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. Cancers (Basel). 2021;13(17).","DOI":"10.3390\/cancers13174287"},{"issue":"12","key":"2252_CR49","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1007\/s11427-022-2289-6","volume":"66","author":"J Wang","year":"2023","unstructured":"Wang J, Wang W, Ma F, Qian H. A hidden translatome in tumors-the coding lncRNAs. Sci China Life Sci. 2023;66(12):2755\u201372.","journal-title":"Sci China Life Sci"},{"issue":"1","key":"2252_CR50","first-page":"242","volume":"178","author":"S van Heesch","year":"2019","unstructured":"van Heesch S, Witte F, Schneider-Lunitz V, Schulz JF, Adami E, Faber AB, et al. Translational Landsc Hum Heart Cell. 2019;178(1):242\u201360. e29.","journal-title":"Translational Landsc Hum Heart Cell"},{"issue":"1","key":"2252_CR51","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13045-024-01591-0","volume":"17","author":"Y Zhang","year":"2024","unstructured":"Zhang Y. LncRNA-encoded peptides in cancer. J Hematol Oncol. 2024;17(1):66.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"2252_CR52","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41580-020-00315-9","volume":"22","author":"L Statello","year":"2021","unstructured":"Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22(2):96\u2013118.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"9","key":"2252_CR53","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ni.3771","volume":"18","author":"YG Chen","year":"2017","unstructured":"Chen YG, Satpathy AT, Chang HY. Gene regulation in the immune system by long noncoding RNAs. Nat Immunol. 2017;18(9):962\u201372.","journal-title":"Nat Immunol"},{"issue":"1","key":"2252_CR54","first-page":"151","volume":"1856","author":"A Bhan","year":"2015","unstructured":"Bhan A, Mandal SS. LncRNA HOTAIR: A master regulator of chromatin dynamics and cancer. Biochim Biophys Acta. 2015;1856(1):151\u201364.","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"2252_CR55","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/nbt.1914","volume":"29","author":"JR Prensner","year":"2011","unstructured":"Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, Brenner JC, et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol. 2011;29(8):742\u20139.","journal-title":"Nat Biotechnol"},{"issue":"7291","key":"2252_CR56","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/nature08975","volume":"464","author":"RA Gupta","year":"2010","unstructured":"Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464(7291):1071\u20136.","journal-title":"Nature"},{"issue":"2","key":"2252_CR57","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/onc.2008.373","volume":"28","author":"M Mourtada-Maarabouni","year":"2009","unstructured":"Mourtada-Maarabouni M, Pickard MR, Hedge VL, Farzaneh F, Williams GT. GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene. 2009;28(2):195\u2013208.","journal-title":"Oncogene"},{"issue":"107","key":"2252_CR58","first-page":"ra8","volume":"3","author":"T Kino","year":"2010","unstructured":"Kino T, Hurt DE, Ichijo T, Nader N, Chrousos GP. Noncoding RNA gas5 is a growth arrest- and starvation-associated repressor of the glucocorticoid receptor. Sci Signal. 2010;3(107):ra8.","journal-title":"Sci Signal"},{"key":"2252_CR59","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ncrna.2024.09.002","volume":"10","author":"Y Perez-Navarro","year":"2025","unstructured":"Perez-Navarro Y, Salinas-Vera YM, Lopez-Camarillo C, Figueroa-Angulo EE, Alvarez-Sanchez ME. The role of long non-coding RNA NORAD in digestive system tumors. Noncoding RNA Res. 2025;10:55\u201362.","journal-title":"Noncoding RNA Res"},{"issue":"3","key":"2252_CR60","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrm.2017.104","volume":"19","author":"JD Ransohoff","year":"2018","unstructured":"Ransohoff JD, Wei Y, Khavari PA. The functions and unique features of long intergenic non-coding RNA. Nat Rev Mol Cell Biol. 2018;19(3):143\u201357.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"2252_CR61","first-page":"925","volume":"10","author":"L Ma","year":"2013","unstructured":"Ma L, Bajic VB, Zhang Z. On the classification of long non-coding RNAs. RNA Biol. 2013;10(6):925\u201333.","journal-title":"RNA Biol"},{"issue":"7","key":"2252_CR62","doi-asserted-by":"crossref","first-page":"e1009683","DOI":"10.1371\/journal.pgen.1009683","volume":"17","author":"CAG Perez","year":"2021","unstructured":"Perez CAG, Adachi S, Nong QD, Adhitama N, Matsuura T, Natsume T, et al. Sense-overlapping lncRNA as a decoy of translational repressor protein for dimorphic gene expression. PLoS Genet. 2021;17(7):e1009683.","journal-title":"PLoS Genet"},{"issue":"12","key":"2252_CR63","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1261\/rna.043968.113","volume":"20","author":"X Zhang","year":"2014","unstructured":"Zhang X, Li H, Burnett JC, Rossi JJ. The role of antisense long noncoding RNA in small RNA-triggered gene activation. RNA. 2014;20(12):1916\u201328.","journal-title":"RNA"},{"issue":"3","key":"2252_CR64","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ncrna.2018.03.001","volume":"3","author":"MM Balas","year":"2018","unstructured":"Balas MM, Johnson AM. Exploring the mechanisms behind long noncoding RNAs and cancer. Noncoding RNA Res. 2018;3(3):108\u201317.","journal-title":"Noncoding RNA Res"},{"key":"2252_CR65","doi-asserted-by":"crossref","unstructured":"Qiu M, Chen Y, Zeng C. Biological functions of circRNA in regulating the hallmarks of gastrointestinal cancer (Review). Int J Oncol. 2024;64(5).","DOI":"10.3892\/ijo.2024.5637"},{"issue":"7","key":"2252_CR66","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2174\/1389202922666210331130722","volume":"22","author":"Y Liang","year":"2021","unstructured":"Liang Y, Liu N, Yang L, Tang J, Wang Y, Mei M. A Brief Review of circRNA Biogenesis, Detection, and Function. Curr Genomics. 2021;22(7):485\u201395.","journal-title":"Curr Genomics"},{"issue":"7","key":"2252_CR67","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1186\/s13059-014-0409-z","volume":"15","author":"JU Guo","year":"2014","unstructured":"Guo JU, Agarwal V, Guo H, Bartel DP. Expanded identification and characterization of mammalian circular RNAs. Genome Biol. 2014;15(7):409.","journal-title":"Genome Biol"},{"key":"2252_CR68","doi-asserted-by":"crossref","first-page":"665246","DOI":"10.3389\/fonc.2021.665246","volume":"11","author":"N Fang","year":"2021","unstructured":"Fang N, Ding GW, Ding H, Li J, Liu C, Lv L, et al. Research Progress of Circular RNA in Gastrointestinal Tumors. Front Oncol. 2021;11:665246.","journal-title":"Front Oncol"},{"issue":"7","key":"2252_CR69","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1002\/cam4.1574","volume":"7","author":"L Fu","year":"2018","unstructured":"Fu L, Jiang Z, Li T, Hu Y, Guo J. Circular RNAs in hepatocellular carcinoma: Functions and implications. Cancer Med. 2018;7(7):3101\u20139.","journal-title":"Cancer Med"},{"key":"2252_CR70","doi-asserted-by":"crossref","unstructured":"Piwecka M, Glazar P, Hernandez-Miranda LR, Memczak S, Wolf SA, Rybak-Wolf A et al. Loss of a mammalian circular RNA locus causes miRNA deregulation and affects brain function. Science. 2017;357(6357).","DOI":"10.1126\/science.aam8526"},{"issue":"7441","key":"2252_CR71","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature11993","volume":"495","author":"TB Hansen","year":"2013","unstructured":"Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495(7441):384\u20138.","journal-title":"Nature"},{"issue":"1","key":"2252_CR72","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12943-019-1094-z","volume":"18","author":"F Yang","year":"2019","unstructured":"Yang F, Hu A, Li D, Wang J, Guo Y, Liu Y, et al. Circ-HuR suppresses HuR expression and gastric cancer progression by inhibiting CNBP transactivation. Mol Cancer. 2019;18(1):158.","journal-title":"Mol Cancer"},{"issue":"6","key":"2252_CR73","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.cell.2015.02.014","volume":"160","author":"SJ Conn","year":"2015","unstructured":"Conn SJ, Pillman KA, Toubia J, Conn VM, Salmanidis M, Phillips CA, et al. The RNA binding protein quaking regulates formation of circRNAs. Cell. 2015;160(6):1125\u201334.","journal-title":"Cell"},{"issue":"5","key":"2252_CR74","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/cr.2017.31","volume":"27","author":"Y Yang","year":"2017","unstructured":"Yang Y, Fan X, Mao M, Song X, Wu P, Zhang Y, et al. Extensive translation of circular RNAs driven by N(6)-methyladenosine. Cell Res. 2017;27(5):626\u201341.","journal-title":"Cell Res"},{"issue":"3","key":"2252_CR75","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/jnci\/djx166","volume":"110","author":"Y Yang","year":"2018","unstructured":"Yang Y, Gao X, Zhang M, Yan S, Sun C, Xiao F, et al. Novel Role of FBXW7 Circular RNA in Repressing Glioma Tumorigenesis. J Natl Cancer Inst. 2018;110(3):304\u201315.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2252_CR76","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nsmb.2959","volume":"22","author":"Z Li","year":"2015","unstructured":"Li Z, Huang C, Bao C, Chen L, Lin M, Wang X, et al. Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol. 2015;22(3):256\u201364.","journal-title":"Nat Struct Mol Biol"},{"issue":"8","key":"2252_CR77","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1136\/jmg.40.8.e100","volume":"40","author":"F Gualandi","year":"2003","unstructured":"Gualandi F, Trabanelli C, Rimessi P, Calzolari E, Toffolatti L, Patarnello T, et al. Multiple exon skipping and RNA circularisation contribute to the severe phenotypic expression of exon 5 dystrophin deletion. J Med Genet. 2003;40(8):e100.","journal-title":"J Med Genet"},{"issue":"1","key":"2252_CR78","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.molcel.2014.08.019","volume":"56","author":"R Ashwal-Fluss","year":"2014","unstructured":"Ashwal-Fluss R, Meyer M, Pamudurti NR, Ivanov A, Bartok O, Hanan M, et al. circRNA biogenesis competes with pre-mRNA splicing. Mol Cell. 2014;56(1):55\u201366.","journal-title":"Mol Cell"},{"issue":"1","key":"2252_CR79","first-page":"14","volume":"19","author":"Y Zeng","year":"2021","unstructured":"Zeng Y, Zou Y, Gao G, Zheng S, Wu S, Xie X, et al. The biogenesis, function and clinical significance of circular RNAs in breast cancer. Cancer Biol Med. 2021;19(1):14\u201329.","journal-title":"Cancer Biol Med"},{"issue":"10","key":"2252_CR80","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.2217\/epi-2019-0093","volume":"11","author":"Y Kong","year":"2019","unstructured":"Kong Y, Yang L, Wei W, Lyu N, Zou Y, Gao G, et al. CircPLK1 sponges miR-296-5p to facilitate triple-negative breast cancer progression. Epigenomics. 2019;11(10):1163\u201376.","journal-title":"Epigenomics"},{"key":"2252_CR81","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.2147\/CMAR.S167863","volume":"10","author":"P Shi","year":"2018","unstructured":"Shi P, Sun J, He B, Song H, Li Z, Kong W, et al. Profiles of differentially expressed circRNAs in esophageal and breast cancer. Cancer Manag Res. 2018;10:2207\u201321.","journal-title":"Cancer Manag Res"},{"key":"2252_CR82","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cca.2017.10.011","volume":"487","author":"WB Yin","year":"2018","unstructured":"Yin WB, Yan MG, Fang X, Guo JJ, Xiong W, Zhang RP. Circulating circular RNA hsa_circ_0001785 acts as a diagnostic biomarker for breast cancer detection. Clin Chim Acta. 2018;487:363\u20138.","journal-title":"Clin Chim Acta"},{"issue":"11","key":"2252_CR83","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1089\/dna.2017.3862","volume":"36","author":"YY Tang","year":"2017","unstructured":"Tang YY, Zhao P, Zou TN, Duan JJ, Zhi R, Yang SY, et al. Circular RNA hsa_circ_0001982 Promotes Breast Cancer Cell Carcinogenesis Through Decreasing miR-143. DNA Cell Biol. 2017;36(11):901\u20138.","journal-title":"DNA Cell Biol"},{"issue":"2","key":"2252_CR84","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.immuni.2011.07.010","volume":"35","author":"N Zhang","year":"2011","unstructured":"Zhang N, Bevan MJ. CD8(+) T cells: foot soldiers of the immune system. Immunity. 2011;35(2):161\u20138.","journal-title":"Immunity"},{"key":"2252_CR85","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","volume":"236","author":"LM Francisco","year":"2010","unstructured":"Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219\u201342.","journal-title":"Immunol Rev"},{"key":"2252_CR86","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.2147\/OTT.S105862","volume":"9","author":"X Wang","year":"2016","unstructured":"Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 2016;9:5023\u201339.","journal-title":"Onco Targets Ther"},{"issue":"4","key":"2252_CR87","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"1\u20132","key":"2252_CR88","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/10932607251325751","volume":"33","author":"A Mardi","year":"2025","unstructured":"Mardi A, Aghebati-Maleki L. Bispecific antibodies (bsAbs) directed against PD-1\/PD-L1 and CTLA-4; a mini review. Hum Antibodies. 2025;33(1\u20132):3\u20139.","journal-title":"Hum Antibodies"},{"issue":"6","key":"2252_CR89","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1084\/jem.20112741","volume":"209","author":"T Yokosuka","year":"2012","unstructured":"Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med. 2012;209(6):1201\u201317.","journal-title":"J Exp Med"},{"issue":"3","key":"2252_CR90","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S1074-7613(04)00051-2","volume":"20","author":"X Zhang","year":"2004","unstructured":"Zhang X, Schwartz JC, Guo X, Bhatia S, Cao E, Lorenz M, et al. Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity. 2004;20(3):337\u201347.","journal-title":"Immunity"},{"issue":"1","key":"2252_CR91","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","volume":"21","author":"KC Ohaegbulam","year":"2015","unstructured":"Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21(1):24\u201333.","journal-title":"Trends Mol Med"},{"issue":"49","key":"2252_CR92","doi-asserted-by":"crossref","first-page":"17174","DOI":"10.1073\/pnas.0406351101","volume":"101","author":"RH Thompson","year":"2004","unstructured":"Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A. 2004;101(49):17174\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2252_CR93","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/03936155231214273","volume":"39","author":"D Gompelmann","year":"2024","unstructured":"Gompelmann D, Sarova P, Mosleh B, Papaporfyriou A, Oberndorfer F, Idzko M, et al. PD-L1 assessment in lung cancer biopsies-pitfalls and limitations. Int J Biol Markers. 2024;39(1):3\u20138.","journal-title":"Int J Biol Markers"},{"issue":"3","key":"2252_CR94","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/85330","volume":"2","author":"Y Latchman","year":"2001","unstructured":"Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2(3):261\u20138.","journal-title":"Nat Immunol"},{"issue":"5","key":"2252_CR95","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.immuni.2016.05.002","volume":"44","author":"FA Schildberg","year":"2016","unstructured":"Schildberg FA, Klein SR, Freeman GJ, Sharpe AH. Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity. 2016;44(5):955\u201372.","journal-title":"Immunity"},{"issue":"7655","key":"2252_CR96","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","volume":"545","author":"SR Gordon","year":"2017","unstructured":"Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545(7655):495\u20139.","journal-title":"Nature"},{"issue":"6382","key":"2252_CR97","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350\u20135.","journal-title":"Science"},{"issue":"1","key":"2252_CR98","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.drudis.2019.11.003","volume":"25","author":"S Singh","year":"2020","unstructured":"Singh S, Hassan D, Aldawsari HM, Molugulu N, Shukla R, Kesharwani P. Immune checkpoint inhibitors: a promising anticancer therapy. Drug Discov Today. 2020;25(1):223\u20139.","journal-title":"Drug Discov Today"},{"issue":"8","key":"2252_CR99","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1200\/JCO.2015.63.7421","volume":"34","author":"DF McDermott","year":"2016","unstructured":"McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O, et al. Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. J Clin Oncol. 2016;34(8):833\u201342.","journal-title":"J Clin Oncol"},{"issue":"9","key":"2252_CR100","doi-asserted-by":"crossref","first-page":"e180077","DOI":"10.1001\/jamaoncol.2018.0077","volume":"4","author":"SP D\u2019Angelo","year":"2018","unstructured":"D\u2019Angelo SP, Russell J, Lebbe C, Chmielowski B, Gambichler T, Grob JJ, et al. Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial. JAMA Oncol. 2018;4(9):e180077.","journal-title":"JAMA Oncol"},{"issue":"2","key":"2252_CR101","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamaoncol.2018.4628","volume":"5","author":"LL Siu","year":"2019","unstructured":"Siu LL, Even C, Mesia R, Remenar E, Daste A, Delord JP, et al. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low\/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial. JAMA Oncol. 2019;5(2):195\u2013203.","journal-title":"JAMA Oncol"},{"issue":"1","key":"2252_CR102","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s13046-019-1266-0","volume":"38","author":"S Kruger","year":"2019","unstructured":"Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, et al. Advances in cancer immunotherapy 2019 - latest trends. J Exp Clin Cancer Res. 2019;38(1):268.","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"2252_CR103","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1136\/jclinpath-2017-204788","volume":"71","author":"EK Bagir","year":"2018","unstructured":"Bagir EK, Acikalin A, Avci A, Gumurdulu D, Paydas S. PD-1 and PD-L1 expression in thymic epithelial tumours and non-neoplastic thymus. J Clin Pathol. 2018;71(7):637\u201341.","journal-title":"J Clin Pathol"},{"issue":"9","key":"2252_CR104","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0611533104","volume":"104","author":"J Hamanishi","year":"2007","unstructured":"Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8\u2009+\u2009T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007;104(9):3360\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2252_CR105","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40364-020-00212-5","volume":"8","author":"JY Sun","year":"2020","unstructured":"Sun JY, Zhang D, Wu S, Xu M, Zhou X, Lu XJ, et al. Resistance to PD-1\/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. Biomark Res. 2020;8(1):35.","journal-title":"Biomark Res"},{"issue":"19","key":"2252_CR106","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"issue":"2","key":"2252_CR107","doi-asserted-by":"crossref","first-page":"157","DOI":"10.21147\/j.issn.1000-9604.2018.02.01","volume":"30","author":"M Song","year":"2018","unstructured":"Song M, Chen X, Wang L, Zhang Y. Future of anti-PD-1\/PD-L1 applications: Combinations with other therapeutic regimens. Chin J Cancer Res. 2018;30(2):157\u201372.","journal-title":"Chin J Cancer Res"},{"issue":"16","key":"2252_CR108","doi-asserted-by":"crossref","first-page":"7065","DOI":"10.1158\/0008-5472.CAN-05-1783","volume":"65","author":"MV Iorio","year":"2005","unstructured":"Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65(16):7065\u201370.","journal-title":"Cancer Res"},{"issue":"7175","key":"2252_CR109","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nature06487","volume":"451","author":"SF Tavazoie","year":"2008","unstructured":"Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008;451(7175):147\u201352.","journal-title":"Nature"},{"issue":"6","key":"2252_CR110","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.cell.2009.03.047","volume":"137","author":"S Valastyan","year":"2009","unstructured":"Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, Wang ZC, et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell. 2009;137(6):1032\u201346.","journal-title":"Cell"},{"key":"2252_CR111","doi-asserted-by":"crossref","first-page":"118939","DOI":"10.1016\/j.lfs.2020.118939","volume":"267","author":"S Azarbarzin","year":"2021","unstructured":"Azarbarzin S, Hosseinpour-Feizi MA, Banan Khojasteh SM, Baradaran B, Safaralizadeh R. MicroRNA\u2009\u2013\u2009383-5p restrains the proliferation and migration of breast cancer cells and promotes apoptosis via inhibition of PD-L1. Life Sci. 2021;267:118939.","journal-title":"Life Sci"},{"issue":"1","key":"2252_CR112","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s10528-025-11057-8","volume":"64","author":"A Mardi","year":"2026","unstructured":"Mardi A, Ghovahi A, Abbasvandi F, Amani D. Experimental Validation of miR-4443, miR-572, and miR-150-5p in Serum and Tissue of Breast Cancer Patients as a Potential Diagnostic Biomarker: A Study Based on Bioinformatics Prediction. Biochem Genet. 2026;64(1):1117\u201344.","journal-title":"Biochem Genet"},{"key":"2252_CR113","doi-asserted-by":"crossref","first-page":"31430","DOI":"10.34172\/bi.31430","volume":"15","author":"B Naseri","year":"2025","unstructured":"Naseri B, Mardi A, Shekari N, Shajari N, Abdolzadeh S, Khorramdelazad H, et al. Ambivalent roles of miRNAs in cancer development via modulating tumor-associated innate immune cells. Bioimpacts. 2025;15:31430.","journal-title":"Bioimpacts"},{"key":"2252_CR114","doi-asserted-by":"crossref","unstructured":"Shadbad MA, Safaei S, Brunetti O, Derakhshani A, Lotfinejad P, Mokhtarzadeh A et al. A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery. Genes (Basel). 2021;12(8).","DOI":"10.3390\/genes12081206"},{"key":"2252_CR115","doi-asserted-by":"crossref","unstructured":"Wang Q, Lin W, Tang X, Li S, Guo L, Lin Y et al. The Roles of microRNAs in Regulating the Expression of PD-1\/PD-L1 Immune Checkpoint. Int J Mol Sci. 2017;18(12).","DOI":"10.3390\/ijms18122540"},{"issue":"3","key":"2252_CR116","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/sji.12577","volume":"86","author":"A Grenda","year":"2017","unstructured":"Grenda A, Krawczyk P. New Dancing Couple: PD-L1 and MicroRNA. Scand J Immunol. 2017;86(3):130\u20134.","journal-title":"Scand J Immunol"},{"issue":"13","key":"2252_CR117","doi-asserted-by":"crossref","first-page":"21609","DOI":"10.18632\/oncotarget.15450","volume":"8","author":"M Cioffi","year":"2017","unstructured":"Cioffi M, Trabulo SM, Vallespinos M, Raj D, Kheir TB, Lin ML, et al. The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1. Oncotarget. 2017;8(13):21609\u201325.","journal-title":"Oncotarget"},{"key":"2252_CR118","doi-asserted-by":"crossref","first-page":"144892","DOI":"10.1016\/j.gene.2020.144892","volume":"754","author":"F Rahmani","year":"2020","unstructured":"Rahmani F, Tadayyon Tabrizi A, Hashemian P, Alijannejad S, Rahdar HA, Ferns GA, et al. Role of regulatory miRNAs of the Wnt\/ beta-catenin signaling pathway in tumorigenesis of breast cancer. Gene. 2020;754:144892.","journal-title":"Gene"},{"issue":"4","key":"2252_CR119","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.celrep.2016.06.051","volume":"16","author":"R Lesurf","year":"2016","unstructured":"Lesurf R, Aure MR, Mork HH, Vitelli V, Oslo Breast Cancer Research C, Lundgren S, et al. Molecular Features of Subtype-Specific Progression from Ductal Carcinoma In Situ to Invasive Breast Cancer. Cell Rep. 2016;16(4):1166\u201379.","journal-title":"Cell Rep"},{"issue":"1","key":"2252_CR120","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13058-017-0812-y","volume":"19","author":"MR Aure","year":"2017","unstructured":"Aure MR, Vitelli V, Jernstrom S, Kumar S, Krohn M, Due EU, et al. Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome. Breast Cancer Res. 2017;19(1):44.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"2252_CR121","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13073-015-0135-5","volume":"7","author":"MR Aure","year":"2015","unstructured":"Aure MR, Jernstrom S, Krohn M, Vollan HK, Due EU, Rodland E, et al. Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer. Genome Med. 2015;7(1):21.","journal-title":"Genome Med"},{"issue":"4","key":"2252_CR122","doi-asserted-by":"crossref","first-page":"203","DOI":"10.21037\/atm-22-97","volume":"10","author":"M Yang","year":"2022","unstructured":"Yang M, Xiao R, Wang X, Xiong Y, Duan Z, Li D, et al. MiR-93-5p regulates tumorigenesis and tumor immunity by targeting PD-L1\/CCND1 in breast cancer. Ann Transl Med. 2022;10(4):203.","journal-title":"Ann Transl Med"},{"issue":"1","key":"2252_CR123","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s11033-022-08047-z","volume":"50","author":"S Deng","year":"2023","unstructured":"Deng S, Wang M, Wang C, Zeng Y, Qin X, Tan Y, et al. p53 downregulates PD-L1 expression via miR-34a to inhibit the growth of triple-negative breast cancer cells: a potential clinical immunotherapeutic target. Mol Biol Rep. 2023;50(1):577\u201387.","journal-title":"Mol Biol Rep"},{"issue":"10","key":"2252_CR124","doi-asserted-by":"crossref","first-page":"e0186658","DOI":"10.1371\/journal.pone.0186658","volume":"12","author":"C Johannessen","year":"2017","unstructured":"Johannessen C, Moi L, Kiselev Y, Pedersen MI, Dalen SM, Braaten T, et al. Expression and function of the miR-143\/145 cluster in vitro and in vivo in human breast cancer. PLoS ONE. 2017;12(10):e0186658.","journal-title":"PLoS ONE"},{"issue":"1","key":"2252_CR125","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/s41598-023-27415-8","volume":"13","author":"S Hajibabaei","year":"2023","unstructured":"Hajibabaei S, Sotoodehnejadnematalahi F, Nafissi N, Zeinali S, Azizi M. Aberrant promoter hypermethylation of miR-335 and miR-145 is involved in breast cancer PD-L1 overexpression. Sci Rep. 2023;13(1):1003.","journal-title":"Sci Rep"},{"key":"2252_CR126","doi-asserted-by":"crossref","first-page":"118239","DOI":"10.1016\/j.lfs.2020.118239","volume":"259","author":"N Dastmalchi","year":"2020","unstructured":"Dastmalchi N, Hosseinpourfeizi MA, Khojasteh SMB, Baradaran B, Safaralizadeh R. Tumor suppressive activity of miR-424-5p in breast cancer cells through targeting PD-L1 and modulating PTEN\/PI3K\/AKT\/mTOR signaling pathway. Life Sci. 2020;259:118239.","journal-title":"Life Sci"},{"key":"2252_CR127","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1038\/srep03444","volume":"3","author":"T Valovka","year":"2013","unstructured":"Valovka T, Schonfeld M, Raffeiner P, Breuker K, Dunzendorfer-Matt T, Hartl M, et al. Transcriptional control of DNA replication licensing by Myc. Sci Rep. 2013;3:3444.","journal-title":"Sci Rep"},{"issue":"Suppl 3","key":"2252_CR128","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000088478","volume":"69","author":"P Carmeliet","year":"2005","unstructured":"Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005;69(Suppl 3):4\u201310.","journal-title":"Oncology"},{"key":"2252_CR129","doi-asserted-by":"crossref","first-page":"173933","DOI":"10.1016\/j.ejphar.2021.173933","volume":"896","author":"M Rasoolnezhad","year":"2021","unstructured":"Rasoolnezhad M, Safaralizadeh R, Hosseinpourfeizi MA, Banan-Khojasteh SM, Baradaran B. MiRNA-138-5p: A strong tumor suppressor targeting PD-L-1 inhibits proliferation and motility of breast cancer cells and induces apoptosis. Eur J Pharmacol. 2021;896:173933.","journal-title":"Eur J Pharmacol"},{"key":"2252_CR130","doi-asserted-by":"crossref","first-page":"851004","DOI":"10.3389\/fimmu.2022.851004","volume":"13","author":"Y Guo","year":"2022","unstructured":"Guo Y, Xie Y, Luo Y. The Role of Long Non-Coding RNAs in the Tumor Immune Microenvironment. Front Immunol. 2022;13:851004.","journal-title":"Front Immunol"},{"issue":"4","key":"2252_CR131","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ccell.2016.03.010","volume":"29","author":"AM Schmitt","year":"2016","unstructured":"Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29(4):452\u201363.","journal-title":"Cancer Cell"},{"issue":"12","key":"2252_CR132","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1631\/jzus.B2300067","volume":"24","author":"Q Yang","year":"2023","unstructured":"Yang Q, Fu Y, Wang J, Yang H, Zhang X. Roles of lncRNA in the diagnosis and prognosis of triple-negative breast cancer. J Zhejiang Univ Sci B. 2023;24(12):1123\u201340.","journal-title":"J Zhejiang Univ Sci B"},{"key":"2252_CR133","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.intimp.2018.09.031","volume":"65","author":"X Li","year":"2018","unstructured":"Li X, Li N. LncRNAs on guard. Int Immunopharmacol. 2018;65:60\u20133.","journal-title":"Int Immunopharmacol"},{"issue":"9","key":"2252_CR134","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1002\/jcp.26568","volume":"233","author":"WD Yu","year":"2018","unstructured":"Yu WD, Wang H, He QF, Xu Y, Wang XC. Long noncoding RNAs in cancer-immunity cycle. J Cell Physiol. 2018;233(9):6518\u201323.","journal-title":"J Cell Physiol"},{"issue":"16","key":"2252_CR135","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.1093\/nar\/gkq285","volume":"38","author":"J Wang","year":"2010","unstructured":"Wang J, Liu X, Wu H, Ni P, Gu Z, Qiao Y, et al. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res. 2010;38(16):5366\u201383.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"2252_CR136","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.cell.2011.09.028","volume":"147","author":"M Cesana","year":"2011","unstructured":"Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M, et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell. 2011;147(2):358\u201369.","journal-title":"Cell"},{"issue":"2","key":"2252_CR137","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3892\/ol.2021.12854","volume":"22","author":"A Samir","year":"2021","unstructured":"Samir A, Tawab RA, El Tayebi HM. Long non-coding RNAs XIST and MALAT1 hijack the PD-L1 regulatory signaling pathway in breast cancer subtypes. Oncol Lett. 2021;22(2):593.","journal-title":"Oncol Lett"},{"key":"2252_CR138","doi-asserted-by":"crossref","unstructured":"Zheng L, Zhang Y, Fu Y, Gong H, Guo J, Wu K et al. Long non-coding RNA MALAT1 regulates BLCAP mRNA expression through binding to miR-339-5p and promotes poor prognosis in breast cancer. Biosci Rep. 2019;39(2).","DOI":"10.1042\/BSR20181284"},{"issue":"11","key":"2252_CR139","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1158\/2326-6066.CIR-23-0045","volume":"11","author":"O Adewunmi","year":"2023","unstructured":"Adewunmi O, Shen Y, Zhang XH, Rosen JM. Targeted Inhibition of lncRNA Malat1 Alters the Tumor Immune Microenvironment in Preclinical Syngeneic Mouse Models of Triple-Negative Breast Cancer. Cancer Immunol Res. 2023;11(11):1462\u201379.","journal-title":"Cancer Immunol Res"},{"key":"2252_CR140","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.3389\/fonc.2019.01459","volume":"9","author":"EA Salama","year":"2019","unstructured":"Salama EA, Adbeltawab RE, El Tayebi HM. XIST and TSIX: Novel Cancer Immune Biomarkers in PD-L1-Overexpressing Breast Cancer Patients. Front Oncol. 2019;9:1459.","journal-title":"Front Oncol"},{"issue":"28","key":"2252_CR141","doi-asserted-by":"crossref","first-page":"43256","DOI":"10.18632\/oncotarget.9673","volume":"7","author":"YS Huang","year":"2016","unstructured":"Huang YS, Chang CC, Lee SS, Jou YS, Shih HM. Xist reduction in breast cancer upregulates AKT phosphorylation via HDAC3-mediated repression of PHLPP1 expression. Oncotarget. 2016;7(28):43256\u201366.","journal-title":"Oncotarget"},{"issue":"4","key":"2252_CR142","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.bbrc.2018.03.104","volume":"498","author":"R Zheng","year":"2018","unstructured":"Zheng R, Lin S, Guan L, Yuan H, Liu K, Liu C, et al. Long non-coding RNA XIST inhibited breast cancer cell growth, migration, and invasion via miR-155\/CDX1 axis. Biochem Biophys Res Commun. 2018;498(4):1002\u20138.","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"2252_CR143","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.celrep.2015.04.039","volume":"11","author":"S Gayen","year":"2015","unstructured":"Gayen S, Maclary E, Buttigieg E, Hinten M, Kalantry S. A Primary Role for the Tsix lncRNA in Maintaining Random X-Chromosome Inactivation. Cell Rep. 2015;11(8):1251\u201365.","journal-title":"Cell Rep"},{"issue":"9","key":"2252_CR144","doi-asserted-by":"crossref","first-page":"e12855","DOI":"10.1111\/cpr.12855","volume":"53","author":"M Zhang","year":"2020","unstructured":"Zhang M, Wang N, Song P, Fu Y, Ren Y, Li Z, et al. LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1. Cell Prolif. 2020;53(9):e12855.","journal-title":"Cell Prolif"},{"issue":"1","key":"2252_CR145","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/01478885.2019.1667126","volume":"43","author":"NA Kamel","year":"2020","unstructured":"Kamel NA, Abdelzaher E, Elgebaly O, Ibrahim SA. Reduced expression of GATA3 predicts progression in non-muscle invasive urothelial carcinoma of the urinary bladder. J Histotechnol. 2020;43(1):21\u20138.","journal-title":"J Histotechnol"},{"issue":"6","key":"2252_CR146","first-page":"3426","volume":"11","author":"G Yin","year":"2019","unstructured":"Yin G, Liu Z, Wang Y, Sun L, Wang L, Yao B, et al. ZNF503 accelerates aggressiveness of hepatocellular carcinoma cells by down-regulation of GATA3 expression and regulated by microRNA-495. Am J Transl Res. 2019;11(6):3426\u201337.","journal-title":"Am J Transl Res"},{"issue":"2","key":"2252_CR147","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41419-023-05609-2","volume":"14","author":"Q Wang","year":"2023","unstructured":"Wang Q, Li G, Ma X, Liu L, Liu J, Yin Y, et al. LncRNA TINCR impairs the efficacy of immunotherapy against breast cancer by recruiting DNMT1 and downregulating MiR-199a-5p via the STAT1-TINCR-USP20-PD-L1 axis. Cell Death Dis. 2023;14(2):76.","journal-title":"Cell Death Dis"},{"key":"2252_CR148","doi-asserted-by":"crossref","first-page":"110128","DOI":"10.1016\/j.abb.2024.110128","volume":"761","author":"H Dong","year":"2024","unstructured":"Dong H, Han J, Chen X, Sun H, Han M, Wang W. LncRNA ZNF649-AS1 promotes trastuzumab resistance and TAM-dependent PD-L1 expression in breast cancer by regulating EXOC7 alternative splicing. Arch Biochem Biophys. 2024;761:110128.","journal-title":"Arch Biochem Biophys"},{"key":"2252_CR149","doi-asserted-by":"crossref","first-page":"118682","DOI":"10.1016\/j.biopha.2025.118682","volume":"193","author":"NS Sherafat","year":"2025","unstructured":"Sherafat NS, Mardi A, Absalan F, Mehmandar-Oskuie A. Circular RNAs as central regulators of metabolic reprogramming and immune responses in the breast cancer microenvironment: A comprehensive review. Biomed Pharmacother. 2025;193:118682.","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"2252_CR150","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.7150\/ijbs.58916","volume":"17","author":"B Fu","year":"2021","unstructured":"Fu B, Liu W, Zhu C, Li P, Wang L, Pan L, et al. Circular RNA circBCBM1 promotes breast cancer brain metastasis by modulating miR-125a\/BRD4 axis. Int J Biol Sci. 2021;17(12):3104\u201317.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"2252_CR151","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13062-023-00397-3","volume":"18","author":"J Li","year":"2023","unstructured":"Li J, Dong X, Kong X, Wang Y, Li Y, Tong Y, et al. Circular RNA hsa_circ_0067842 facilitates tumor metastasis and immune escape in breast cancer through HuR\/CMTM6\/PD-L1 axis. Biol Direct. 2023;18(1):48.","journal-title":"Biol Direct"},{"key":"2252_CR152","doi-asserted-by":"publisher","first-page":"12632","DOI":"10.1038\/ncomms12632","volume":"7","author":"CW Li","year":"2016","unstructured":"Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7:12632.","journal-title":"Nat Commun"},{"key":"2252_CR153","doi-asserted-by":"crossref","unstructured":"Dong LF, Chen FF, Fan YF, Zhang K, Chen HH. circ-0000512 inhibits PD-L1 ubiquitination through sponging miR-622\/CMTM6 axis to promote triple-negative breast cancer and immune escape. J Immunother Cancer. 2023;11(6).","DOI":"10.1136\/jitc-2022-005461"},{"issue":"1","key":"2252_CR154","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41420-024-02197-8","volume":"10","author":"L Liang","year":"2024","unstructured":"Liang L, Gao M, Li W, Tang J, He Q, Zeng F, et al. CircGSK3beta mediates PD-L1 transcription through miR-338-3p\/PRMT5\/H3K4me3 to promote breast cancer cell immune evasion and tumor progression. Cell Death Discov. 2024;10(1):426.","journal-title":"Cell Death Discov"},{"issue":"7","key":"2252_CR155","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s00262-024-03705-6","volume":"73","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Huo W, Li J. circATAD2 mitigates CD8(+) T cells antitumor immune surveillance in breast cancer via IGF2BP3\/m(6)A\/PD-L1 manner. Cancer Immunol Immunother. 2024;73(7):130.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"2252_CR156","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s12026-021-09237-w","volume":"69","author":"L Huang","year":"2021","unstructured":"Huang L, Ma J, Cui M. Circular RNA hsa_circ_0001598 promotes programmed death-ligand-1-mediated immune escape and trastuzumab resistance via sponging miR-1184 in breast cancer cells. Immunol Res. 2021;69(6):558\u201367.","journal-title":"Immunol Res"},{"issue":"1","key":"2252_CR157","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12935-022-02686-9","volume":"22","author":"Y Zheng","year":"2022","unstructured":"Zheng Y, Ren S, Zhang Y, Liu S, Meng L, Liu F, et al. Circular RNA circWWC3 augments breast cancer progression through promoting M2 macrophage polarization and tumor immune escape via regulating the expression and secretion of IL-4. Cancer Cell Int. 2022;22(1):264.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"2252_CR158","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12935-025-03809-8","volume":"25","author":"H Zhang","year":"2025","unstructured":"Zhang H, Gong L, Yu L, Xian C, Ma Z, Wang X, et al. Emerging roles of non-coding RNA derived from extracellular vesicles in regulating PD-1\/PD-L1 pathway: insights into cancer immunotherapy and clinical applications. Cancer Cell Int. 2025;25(1):188.","journal-title":"Cancer Cell Int"},{"key":"2252_CR159","doi-asserted-by":"crossref","unstructured":"Hsu C-Y, Hjazi A, Suliman M, Singh G, Arora V, Shakhlo A et al. Disrupting immune silence: Noncoding RNAs targeting the programmed cell death protein 1\/programmed cell death ligand 1 axis in tumor immunity. J Pharmacol Exp Ther. 2026;393(4).","DOI":"10.1016\/j.jpet.2026.104316"},{"key":"2252_CR160","doi-asserted-by":"crossref","first-page":"114698","DOI":"10.1016\/j.biopha.2023.114698","volume":"162","author":"S Yang","year":"2023","unstructured":"Yang S, Wang X, Zhou X, Hou L, Wu J, Zhang W, et al. ncRNA-mediated ceRNA regulatory network: Transcriptomic insights into breast cancer progression and treatment strategies. Biomed Pharmacother. 2023;162:114698.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"2252_CR161","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3390\/biology12030467","volume":"12","author":"SS Shinde","year":"2023","unstructured":"Shinde SS, Ahmed S, Malik JA, Hani U, Khanam A, Ashraf Bhat F, et al. Therapeutic delivery of tumor suppressor miRNAs for breast cancer treatment. Biology. 2023;12(3):467.","journal-title":"Biology"},{"issue":"9","key":"2252_CR162","first-page":"365","volume":"33","author":"Y Deng","year":"2018","unstructured":"Deng Y, Zhao F, Zhang Z, Sun F, Wang M. Long noncoding RNA SNHG7 promotes the tumor growth and epithelial-to-mesenchymal transition via regulation of miR-34a signals in osteosarcoma. Cancer Biother Radiopharm. 2018;33(9):365\u201372.","journal-title":"Cancer Biother Radiopharm"},{"issue":"3","key":"2252_CR163","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","volume":"16","author":"R Rupaimoole","year":"2017","unstructured":"Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discovery. 2017;16(3):203\u201322.","journal-title":"Nat Rev Drug Discovery"},{"key":"2252_CR164","doi-asserted-by":"crossref","unstructured":"Zhang S, Cheng Z, Wang Y, Han T. The risks of miRNA therapeutics: in a drug target perspective. Drug design, development and therapy. 2021:721\u2009\u2013\u200933.","DOI":"10.2147\/DDDT.S288859"},{"issue":"2","key":"2252_CR165","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/bph.17302","volume":"182","author":"Z Bereczki","year":"2025","unstructured":"Bereczki Z, Benczik B, Balogh OM, Marton S, Puhl E, P\u00e9terv\u00e1ri M, et al. Mitigating off-target effects of small RNAs: conventional approaches, network theory and artificial intelligence. Br J Pharmacol. 2025;182(2):340\u201379.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"2252_CR166","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1186\/s12967-025-06629-6","volume":"23","author":"D Mu","year":"2025","unstructured":"Mu D, Han B, Huang H, Zheng Y, Zhang J, Shi Y. Unraveling the advances of non-coding RNAs on the tumor microenvironment: innovative strategies for cancer therapies. J Translational Med. 2025;23(1):614.","journal-title":"J Translational Med"},{"issue":"1","key":"2252_CR167","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1038\/s41467-018-04791-8","volume":"9","author":"WM Usman","year":"2018","unstructured":"Usman WM, Pham TC, Kwok YY, Vu LT, Ma V, Peng B, et al. Efficient RNA drug delivery using red blood cell extracellular vesicles. Nat Commun. 2018;9(1):2359.","journal-title":"Nat Commun"},{"key":"2252_CR168","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jconrel.2020.08.028","volume":"327","author":"V Simion","year":"2020","unstructured":"Simion V, Henriet E, Juric V, Aquino R, Loussouarn C, Laurent Y, et al. Intracellular trafficking and functional monitoring of miRNA delivery in glioblastoma using lipopolyplexes and the miRNA-ON RILES reporter system. J Controlled Release. 2020;327:429\u201343.","journal-title":"J Controlled Release"},{"key":"2252_CR169","doi-asserted-by":"crossref","first-page":"215798","DOI":"10.1016\/j.canlet.2022.215798","volume":"543","author":"J Yang","year":"2022","unstructured":"Yang J, Liu F, Wang Y, Qu L, Lin A. LncRNAs in tumor metabolic reprogramming and immune microenvironment remodeling. Cancer Lett. 2022;543:215798.","journal-title":"Cancer Lett"},{"issue":"5","key":"2252_CR170","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2174\/0113892029305656240503045154","volume":"25","author":"MS Hussain","year":"2024","unstructured":"Hussain MS, Agrawal M, Shaikh NK, Saraswat N, Bahl G, Maqbool Bhat M, et al. Beyond the genome: deciphering the role of MALAT1 in breast cancer progression. Curr Genom. 2024;25(5):343\u201357.","journal-title":"Curr Genom"},{"issue":"1","key":"2252_CR171","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11033-025-10513-3","volume":"52","author":"MR Moghaddasnejad","year":"2025","unstructured":"Moghaddasnejad MR, Keshavarz A, Mardi A, Sherafat NS, Aghebati-Maleki L, Mohammadi MH. LncRNAs as behind-the-scenes molecules in cancer progression through regulating tumor-associated innate immune system cells. Mol Biol Rep. 2025;52(1):449.","journal-title":"Mol Biol Rep"},{"key":"2252_CR172","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.lungcan.2020.06.037","volume":"147","author":"Q Wang","year":"2020","unstructured":"Wang Q, Li X, Ren S, Su C, Li C, Li W, et al. HOTAIR induces EGFR-TKIs resistance in non-small cell lung cancer through epithelial-mesenchymal transition. Lung Cancer. 2020;147:99\u2013105.","journal-title":"Lung Cancer"},{"issue":"3","key":"2252_CR173","doi-asserted-by":"crossref","first-page":"188899","DOI":"10.1016\/j.bbcan.2023.188899","volume":"1878","author":"A Shabna","year":"2023","unstructured":"Shabna A, Bindhya S, Sidhanth C, Garg M, Ganesan TS. Long non-coding RNAs: fundamental regulators and emerging targets of cancer stem cells. Biochim et Biophys Acta (BBA)-Reviews Cancer. 2023;1878(3):188899.","journal-title":"Biochim et Biophys Acta (BBA)-Reviews Cancer"},{"issue":"2","key":"2252_CR174","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.apsb.2020.10.001","volume":"11","author":"Y Chen","year":"2021","unstructured":"Chen Y, Li Z, Chen X, Zhang S. Long non-coding RNAs: from disease code to drug role. Acta Pharm Sinica B. 2021;11(2):340\u201354.","journal-title":"Acta Pharm Sinica B"},{"key":"2252_CR175","doi-asserted-by":"crossref","unstructured":"Shaath H, Vishnubalaji R, Elango R, Kardousha A, Islam Z, Qureshi R, et al. editors. Long non-coding RNA and RNA-binding protein interactions in cancer: experimental and machine learning approaches. Seminars in cancer biology. Elsevier; 2022.","DOI":"10.1016\/j.semcancer.2022.05.013"},{"issue":"7866","key":"2252_CR176","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41586-021-03633-w","volume":"595","author":"MM Elguindy","year":"2021","unstructured":"Elguindy MM, Mendell JT. NORAD-induced Pumilio phase separation is required for genome stability. Nature. 2021;595(7866):303\u20138.","journal-title":"Nature"},{"key":"2252_CR177","doi-asserted-by":"crossref","first-page":"103917","DOI":"10.1016\/j.jddst.2022.103917","volume":"78","author":"M Bagherzadeh","year":"2022","unstructured":"Bagherzadeh M, Safarkhani M, Daneshgar H, Radmanesh F, Taghavimandi F, Ghadiri AM, et al. Magnetic carbon\u2013based nanocomposite decorated with palladium complex for co-delivery of DOX\/pCRISPR. J Drug Deliv Sci Technol. 2022;78:103917.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"24","key":"2252_CR178","doi-asserted-by":"crossref","first-page":"2309559","DOI":"10.1002\/advs.202309559","volume":"11","author":"J Yuan","year":"2024","unstructured":"Yuan J, Wang Y, Huang Y, Li S, Zhang X, Wu Z, et al. Investigating Novel therapeutic approaches for idiopathic short stature: targeting siRNA and growth hormone delivery to the growth plate using exosome nanoparticles. Adv Sci. 2024;11(24):2309559.","journal-title":"Adv Sci"},{"issue":"1","key":"2252_CR179","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s42003-024-05854-x","volume":"7","author":"D-M Liang","year":"2024","unstructured":"Liang D-M, Li Y-J, Zhang J-X, Shen H-H, Wu C-X, Xie N, et al. m6A-methylated KCTD21-AS1 regulates macrophage phagocytosis through CD47 and cell autophagy through TIPR. Commun Biology. 2024;7(1):215.","journal-title":"Commun Biology"},{"issue":"11","key":"2252_CR180","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41576-019-0158-7","volume":"20","author":"LS Kristensen","year":"2019","unstructured":"Kristensen LS, Andersen MS, Stagsted LV, Ebbesen KK, Hansen TB, Kjems J. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20(11):675\u201391.","journal-title":"Nat Rev Genet"},{"issue":"3","key":"2252_CR181","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1515\/jtim-2025-0029","volume":"13","author":"D Dai","year":"2025","unstructured":"Dai D, Zhang J, Mo Y, Song C, Liu L, Chen ZS, et al. CircPLK1 upregulates ETS1 to confer anthracycline resistance in triple-negative breast cancer. J Transl Int Med. 2025;13(3):267\u201380.","journal-title":"J Transl Int Med"},{"issue":"1","key":"2252_CR182","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12943-020-1135-7","volume":"19","author":"M Lei","year":"2020","unstructured":"Lei M, Zheng G, Ning Q, Zheng J, Dong D. Translation and functional roles of circular RNAs in human cancer. Mol Cancer. 2020;19(1):30.","journal-title":"Mol Cancer"},{"issue":"7995","key":"2252_CR183","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41586-023-06834-7","volume":"625","author":"D Huang","year":"2024","unstructured":"Huang D, Zhu X, Ye S, Zhang J, Liao J, Zhang N, et al. Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides. Nature. 2024;625(7995):593\u2013602.","journal-title":"Nature"},{"key":"2252_CR184","doi-asserted-by":"crossref","first-page":"0723","DOI":"10.34133\/research.0723","volume":"8","author":"A Lin","year":"2025","unstructured":"Lin A, Ye P, Li Z, Jiang A, Liu Z, Cheng Q, et al. Natural killer cell immune checkpoints and their therapeutic targeting in cancer treatment. Research. 2025;8:0723.","journal-title":"Research"},{"issue":"14","key":"2252_CR185","doi-asserted-by":"crossref","first-page":"6422","DOI":"10.7150\/thno.77350","volume":"12","author":"H Li","year":"2022","unstructured":"Li H, Peng K, Yang K, Ma W, Qi S, Yu X, et al. Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies. Theranostics. 2022;12(14):6422.","journal-title":"Theranostics"},{"issue":"1","key":"2252_CR186","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12943-024-02082-z","volume":"23","author":"W Zhang","year":"2024","unstructured":"Zhang W, Xu C, Yang Z, Zhou J, Peng W, Zhang X, et al. Circular RNAs in tumor immunity and immunotherapy. Mol Cancer. 2024;23(1):171.","journal-title":"Mol Cancer"},{"issue":"10","key":"2252_CR187","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.3390\/vaccines11101600","volume":"11","author":"AD Perenkov","year":"2023","unstructured":"Perenkov AD, Sergeeva AD, Vedunova MV, Krysko DV. In vitro transcribed RNA-based platform vaccines: past, present, and future. Vaccines. 2023;11(10):1600.","journal-title":"Vaccines"},{"issue":"1","key":"2252_CR188","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1186\/s12967-024-05498-9","volume":"22","author":"Y Li","year":"2024","unstructured":"Li Y, Wang Z, Gao P, Cao D, Dong R, Zhu M, et al. CircRHBDD1 promotes immune escape via IGF2BP2\/PD-L1 signaling and acts as a nanotherapeutic target in gastric cancer. J Translational Med. 2024;22(1):704.","journal-title":"J Translational Med"},{"issue":"1","key":"2252_CR189","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12943-023-01759-1","volume":"22","author":"Z Hu","year":"2023","unstructured":"Hu Z, Chen G, Zhao Y, Gao H, Li L, Yin Y, et al. Exosome-derived circCCAR1 promotes CD8\u2009+\u2009T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma. Mol Cancer. 2023;22(1):55.","journal-title":"Mol Cancer"},{"issue":"10","key":"2252_CR190","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.7150\/jca.111680","volume":"16","author":"Q Bao","year":"2025","unstructured":"Bao Q, Zhang H, Chen P, Wu S, Zou Y, Wang H, et al. The Dual Roles of Circular RNAs in Breast Cancer Distant Metastasis and Their Clinical Applications. J Cancer. 2025;16(10):3270\u201382.","journal-title":"J Cancer"},{"issue":"3","key":"2252_CR191","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1002\/imt2.130","volume":"2","author":"L Liu","year":"2023","unstructured":"Liu L, Xie Y, Yang H, Lin A, Dong M, Wang H, et al. HPVTIMER: A shiny web application for tumor immune estimation in human papillomavirus-associated cancers. Imeta. 2023;2(3):e130.","journal-title":"Imeta"},{"key":"2252_CR192","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.2147\/OTT.S132508","volume":"10","author":"M Robainas","year":"2017","unstructured":"Robainas M, Otano R, Bueno S, Ait-Oudhia S. Understanding the role of PD-L1\/PD1 pathway blockade and autophagy in cancer therapy. Onco Targets Ther. 2017;10:1803\u20137.","journal-title":"Onco Targets Ther"},{"issue":"15","key":"2252_CR193","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.7150\/jca.30425","volume":"10","author":"F Wu","year":"2019","unstructured":"Wu F, Yin Z, Yang L, Fan J, Xu J, Jin Y, et al. Smoking Induced Extracellular Vesicles Release and Their Distinct Properties in Non-Small Cell Lung Cancer. J Cancer. 2019;10(15):3435\u201343.","journal-title":"J Cancer"},{"issue":"4","key":"2252_CR194","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.bbrc.2020.01.170","volume":"526","author":"R Wang","year":"2020","unstructured":"Wang R, Huang Z, Qian C, Wang M, Zheng Y, Jiang R, et al. LncRNA WEE2-AS1 promotes proliferation and inhibits apoptosis in triple negative breast cancer cells via regulating miR-32-5p\/TOB1 axis. Biochem Biophys Res Commun. 2020;526(4):1005\u201312.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"2252_CR195","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/1878-0261.12446","volume":"13","author":"FO Beltran-Anaya","year":"2019","unstructured":"Beltran-Anaya FO, Romero-Cordoba S, Rebollar-Vega R, Arrieta O, Bautista-Pina V, Dominguez-Reyes C, et al. Expression of long non-coding RNA ENSG00000226738 (LncKLHDC7B) is enriched in the immunomodulatory triple-negative breast cancer subtype and its alteration promotes cell migration, invasion, and resistance to cell death. Mol Oncol. 2019;13(4):909\u201327.","journal-title":"Mol Oncol"},{"issue":"8","key":"2252_CR196","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/s41419-018-0869-2","volume":"9","author":"S Wang","year":"2018","unstructured":"Wang S, Ke H, Zhang H, Ma Y, Ao L, Zou L, et al. LncRNA MIR100HG promotes cell proliferation in triple-negative breast cancer through triplex formation with p27 loci. Cell Death Dis. 2018;9(8):805.","journal-title":"Cell Death Dis"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02252-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02252-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02252-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:28:45Z","timestamp":1791973725000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02252-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,19]]},"references-count":196,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2252"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02252-x","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,19]]},"assertion":[{"value":"29 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this manuscript, the authors used ChatGPT to improve the language, grammar, and readability of selected sections of the manuscript. All scientific content, interpretation of the literature, and final editing were performed by the authors, who take full responsibility for the accuracy and integrity of the manuscript.","order":4,"name":"Ethics","label":"Generative AI statement","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"352"}}